This article and associated images are based on a poster originally authored by Sophie O’Neil, Kyle Thompson, Rita Pereira, Emily Russell and Stuart McElroy and presented at ELRIG Drug Discovery 2025 ...

Scientists at UC Davis created a new class of serotonin-targeting molecules using a light-driven chemical method. UC Davis scientists have created a light-based technique that converts amino acids — t ...

Shionogi & Co. Ltd. has synthesized spiroheterocycle derivatives acting as 5-HT2A and 5-HT2C receptor antagonists and/or inverse agonists reported to be useful for the treatment of neurodegeneration.

P silocybin—the psychedelic ingredient found in some “magic” mushrooms—has shown a lot of promise for treating depression and ...

Suven Life Sciences Ltd. has identified 5-HT1A receptor agonists and 5-HT2A receptor antagonists reported to be useful for the treatment of depression, insomnia, schizophrenia, bipolar and cognitive ...

STUART, Fla.--(BUSINESS WIRE)--Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and neurocognitive disorders, announced the publication of its latest ...

Research has already shown the psychedelic drug psilocybin eases depression, PTSD, and anxiety. Now researchers are working ...

This article was originally published on Psychedelic Spotlight and appears here with permission. New study suggests that a non-hallucinogenic LSD analog may hold therapeutic potential for mood ...

It is becoming increasingly accepted that classic psychedelics like LSD, psilocybin, ayahuasca, and mescaline can act as antidepressants and anti-anxiety treatments in addition to causing ...

Receptors mediate the transmission of information between nerve cells. The release of serotonin alters nerve cell activities throughout the brain. At least 14 types of serotonergic receptors can be ...

Toad venom (Chansu), first documented in the "Yaoxing Lun" (Treatise on the Properties of Medicines), is a treasured ...